Q-omics provides the consensus-scored MIR942 profile across patient tissues and cancer cell-line models. MIR942 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR942 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, MIR942 RNA expression shows 11,343 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, BRCA, and LSCC as cancer lineages where MIR942 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR942 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR942 survival associations across molecular data types. MIR942 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR942 RNA expression–survival associations across cancer types. High MIR942 expression shows unfavorable associations in THCA, KIRP, SKCM and MESO, but favorable associations in HNSC and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR942 RNA expression.
This table summarizes MIR942 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR942. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR942 shows higher tumor expression in BRCA, LUSC, LUAD, UCEC, STAD and ESCA. The BRCA box plot shows higher MIR942 RNA expression in tumor versus normal tissue (log2 FC = +0.369, t-test p < 0.001).
This table shows molecular features associated with MIR942 in patient tissues and cancer cell lines. In patient samples, MIR942 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
